Tao Wu, Zhenmin Ren, Xiaorong Liu, Zhihao Xing, Xiaoying Fu, Wujiao Li, Moxian Chen, Defa Li, Yunsheng Chen
{"title":"cerna驱动的儿童β-地中海贫血调节机制的系统鉴定和验证。","authors":"Tao Wu, Zhenmin Ren, Xiaorong Liu, Zhihao Xing, Xiaoying Fu, Wujiao Li, Moxian Chen, Defa Li, Yunsheng Chen","doi":"10.1007/s00277-025-06215-2","DOIUrl":null,"url":null,"abstract":"<div><p>Reactivation of fetal hemoglobin (Hb F, α2γ2) has been demonstrated to be a therapeutic strategy for patients with β-hemoglobinopathies. MicroRNAs (miRNAs) are small noncoding RNAs that regulate gene expression by silencing RNA. Both coding and non-coding RNAs can compete for the same miRNAs, acting as competing endogenous RNAs (ceRNAs). However, the role of ceRNAs in β-thalassemia major (β-TM) and their impact on γ-globin expression remains poorly understood. In this study, we conducted transcriptome sequencing to collect circularRNA (circRNA), miRNA, and mRNAs from β-TM patients and healthy individuals. Through bioinformatics analysis, we constructed a <i>GATA2</i>‑associated ceRNA network, emphasizing the <i>hsa_circ_0005245</i>_<i>hsa-miR-425-3p</i>_<i>GATA2</i> pathway. Validation using qRT-PCR analysis in β-TM samples, RNA immunoprecipitation, and dual-luciferase reporter assays confirmed this pathway. Furthermore, overexpression of <i>hsa_circ_0005245</i>, <i>hsa-miR-425-3p</i>, and <i>GATA2</i> in HUDEP-2 cells individually resulted in elevated γ-globin levels. Our findings identify a novel <i>hsa_circ_0005245</i>_<i>hsa-miR-425-3p</i>_<i>GATA2</i> pathway that regulates γ-globin expression, providing potential insights for the clinical management of β-TM patients.</p></div>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":"104 2","pages":"963 - 972"},"PeriodicalIF":2.4000,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s00277-025-06215-2.pdf","citationCount":"0","resultStr":"{\"title\":\"Systematic identification and validation of ceRNA-driven regulatory mechanisms in pediatric β-Thalassemia major\",\"authors\":\"Tao Wu, Zhenmin Ren, Xiaorong Liu, Zhihao Xing, Xiaoying Fu, Wujiao Li, Moxian Chen, Defa Li, Yunsheng Chen\",\"doi\":\"10.1007/s00277-025-06215-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Reactivation of fetal hemoglobin (Hb F, α2γ2) has been demonstrated to be a therapeutic strategy for patients with β-hemoglobinopathies. MicroRNAs (miRNAs) are small noncoding RNAs that regulate gene expression by silencing RNA. Both coding and non-coding RNAs can compete for the same miRNAs, acting as competing endogenous RNAs (ceRNAs). However, the role of ceRNAs in β-thalassemia major (β-TM) and their impact on γ-globin expression remains poorly understood. In this study, we conducted transcriptome sequencing to collect circularRNA (circRNA), miRNA, and mRNAs from β-TM patients and healthy individuals. Through bioinformatics analysis, we constructed a <i>GATA2</i>‑associated ceRNA network, emphasizing the <i>hsa_circ_0005245</i>_<i>hsa-miR-425-3p</i>_<i>GATA2</i> pathway. Validation using qRT-PCR analysis in β-TM samples, RNA immunoprecipitation, and dual-luciferase reporter assays confirmed this pathway. Furthermore, overexpression of <i>hsa_circ_0005245</i>, <i>hsa-miR-425-3p</i>, and <i>GATA2</i> in HUDEP-2 cells individually resulted in elevated γ-globin levels. Our findings identify a novel <i>hsa_circ_0005245</i>_<i>hsa-miR-425-3p</i>_<i>GATA2</i> pathway that regulates γ-globin expression, providing potential insights for the clinical management of β-TM patients.</p></div>\",\"PeriodicalId\":8068,\"journal\":{\"name\":\"Annals of Hematology\",\"volume\":\"104 2\",\"pages\":\"963 - 972\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2025-02-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://link.springer.com/content/pdf/10.1007/s00277-025-06215-2.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Hematology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://link.springer.com/article/10.1007/s00277-025-06215-2\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Hematology","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s00277-025-06215-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
Systematic identification and validation of ceRNA-driven regulatory mechanisms in pediatric β-Thalassemia major
Reactivation of fetal hemoglobin (Hb F, α2γ2) has been demonstrated to be a therapeutic strategy for patients with β-hemoglobinopathies. MicroRNAs (miRNAs) are small noncoding RNAs that regulate gene expression by silencing RNA. Both coding and non-coding RNAs can compete for the same miRNAs, acting as competing endogenous RNAs (ceRNAs). However, the role of ceRNAs in β-thalassemia major (β-TM) and their impact on γ-globin expression remains poorly understood. In this study, we conducted transcriptome sequencing to collect circularRNA (circRNA), miRNA, and mRNAs from β-TM patients and healthy individuals. Through bioinformatics analysis, we constructed a GATA2‑associated ceRNA network, emphasizing the hsa_circ_0005245_hsa-miR-425-3p_GATA2 pathway. Validation using qRT-PCR analysis in β-TM samples, RNA immunoprecipitation, and dual-luciferase reporter assays confirmed this pathway. Furthermore, overexpression of hsa_circ_0005245, hsa-miR-425-3p, and GATA2 in HUDEP-2 cells individually resulted in elevated γ-globin levels. Our findings identify a novel hsa_circ_0005245_hsa-miR-425-3p_GATA2 pathway that regulates γ-globin expression, providing potential insights for the clinical management of β-TM patients.
期刊介绍:
Annals of Hematology covers the whole spectrum of clinical and experimental hematology, hemostaseology, blood transfusion, and related aspects of medical oncology, including diagnosis and treatment of leukemias, lymphatic neoplasias and solid tumors, and transplantation of hematopoietic stem cells. Coverage includes general aspects of oncology, molecular biology and immunology as pertinent to problems of human blood disease. The journal is associated with the German Society for Hematology and Medical Oncology, and the Austrian Society for Hematology and Oncology.